Virogin Announces its Publication of Homologous Prime Boost Strategy using HER-2 expressing Oncolytic HSV-1 in Vaccines

Vancouver BC Canada, December 05, 2023 Virogin Biotech, a clinical-stage immuno-oncology company, announced its publication in a top peer-reviewed journal Vaccines 2023, 11(12), 1805 with the title “Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor Cells”. This article focuses on the latest research […]

VIROGIN Receives FDA Fast Track Designation for VG161, a Novel Therapy Candidate for the Treatment of Advanced Hepatocellular Carcinoma

Vancouver, British Columbia, July 13, 2023 Virogin Biotech announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of VG161 for patients with advanced unresectable Hepatocellular Carcinoma. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancers and accounts for 75–90% of all primary liver cancers, […]

VG161 granted for FDA Orphan Drug Designation

Vancouver, British Columbia, February 12, 2023 Virogin Biotech announced that it has received a formal letter response from the US Food and Drug Administration (FDA) Office of Orphan Products Development, of which its Class I innovative oncolytic virus product, VG161, has been granted for treatment of Intrahepatic Cholangiocarcinoma (ICC). Intrahepatic Cholangiocarcinoma (ICC) is a rare […]

New Research Progress on VG301 Development

Virogin’s R&D team announced good news just after New Year’s Eve in 2023. Virogin’s global R&D team released the preprint of “HSV-1 Oncolytic Virus Targeting CEACAM6-Expressing Tumors Using a Bispecific T Cell Engager” on BioRxiv. This article focuses on the latest research progress of the company’s newest generation of oncolytic virus product VG301 (product code […]